Savara (SVRA) Consolidated Net Income (2010 - 2026)
Savara (SVRA) posted quarterly Consolidated Net Income of -$39.9 million for Q1 2026, down 49.61% year-over-year from -$79.1 million in Q1 2025, and down 28.83% quarter-over-quarter from -$30.9 million in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Consolidated Net Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Consolidated Net Income for 17 consecutive years, with -$39.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 49.61% year-over-year to -$39.9 million; the TTM figure through Mar 2026 stood at -$132.5 million (down 22.48% YoY), while the FY2025 annual figure was -$266.3 million, down 26.49% from the prior year.
- Consolidated Net Income retreated to -$39.9 million in Q1 2026 per SVRA's latest filing, from -$30.9 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$8.6 million in Q1 2022 and bottomed at -$39.9 million in Q1 2026.
- Historically, Consolidated Net Income has averaged -$21.4 million across 5 years, with a median of -$20.3 million in 2024.
- Annual changes were most pronounced in 2022 — Consolidated Net Income advanced 21.11% — and 2024, when it plunged 85.18%.
- Savara's Consolidated Net Income stood at -$11.3 million in 2022, then plunged by 58.9% to -$17.9 million in 2023, then sank by 78.31% to -$31.9 million in 2024, then climbed by 3.15% to -$30.9 million in 2025, then retreated by 28.83% to -$39.9 million in 2026.
- Business Quant data shows SVRA's Consolidated Net Income at -$39.9 million in Q1 2026, -$30.9 million in Q4 2025, and -$30.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | -40.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.14 Mn |
| Mar 31, 2026 | -37.93 Mn |
| Dec 31, 2025 | -32.22 Mn |
| Sep 30, 2025 | -29.71 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.26 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | -22.12 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.11 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -12.28 Mn |
| Mar 31, 2023 | -12.10 Mn |
| Dec 31, 2022 | -10.26 Mn |
| Sep 30, 2022 | -10.38 Mn |
| Jun 30, 2022 | -9.36 Mn |
| Mar 31, 2022 | -8.13 Mn |
| Dec 31, 2021 | -11.20 Mn |
| Sep 30, 2021 | -10.54 Mn |